| __timestamp | BioCryst Pharmaceuticals, Inc. | HUTCHMED (China) Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 7461000 | 26684000 |
| Thursday, January 1, 2015 | 13047000 | 29829000 |
| Friday, January 1, 2016 | 11253000 | 39578000 |
| Sunday, January 1, 2017 | 13933000 | 43277000 |
| Monday, January 1, 2018 | 29514000 | 48645000 |
| Tuesday, January 1, 2019 | 37121000 | 52934000 |
| Wednesday, January 1, 2020 | 67929000 | 61349000 |
| Friday, January 1, 2021 | 118818000 | 127125000 |
| Saturday, January 1, 2022 | 159371000 | 136106000 |
| Sunday, January 1, 2023 | 213894000 | 133175999 |
Unleashing the power of data
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, HUTCHMED (China) Limited and BioCryst Pharmaceuticals, Inc. have shown distinct strategies in optimizing these costs. From 2014 to 2023, BioCryst's SG&A expenses surged by nearly 280%, peaking in 2023. In contrast, HUTCHMED's expenses grew by approximately 50% over the same period, indicating a more controlled approach.
BioCryst's aggressive increase in SG&A spending, particularly from 2020 onwards, suggests a strategic push for market expansion and product development. Meanwhile, HUTCHMED's steadier growth in expenses reflects a balanced strategy, possibly focusing on sustainable growth and operational efficiency. This divergence in financial strategy highlights the different paths companies can take in the pharmaceutical industry to achieve their business objectives.
SG&A Efficiency Analysis: Comparing Novo Nordisk A/S and HUTCHMED (China) Limited
Pfizer Inc. or BioCryst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs BioCryst Pharmaceuticals, Inc.
United Therapeutics Corporation or HUTCHMED (China) Limited: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and BioCryst Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Insmed Incorporated or BioCryst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Exelixis, Inc. and HUTCHMED (China) Limited
Pharming Group N.V. vs HUTCHMED (China) Limited: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing ADMA Biologics, Inc. and BioCryst Pharmaceuticals, Inc.
Bausch Health Companies Inc. or HUTCHMED (China) Limited: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Bausch Health Companies Inc. and BioCryst Pharmaceuticals, Inc.
Mesoblast Limited and BioCryst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared